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Abstract
Individual differences in response to pharmacologic treatment limits the usefulness of mean data obtained from
randomized controlled trials. These individual differences exist even in genetically uniform inbred mouse strains.
While stratification can be of value in large studies, the individual patient history is the most effective currently
available guide for personalized medicine in psychopharmacology.
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Background
The statistical nature of scientific experiment becomes
clear early on in a scientist’s career. While individuals
without scientific background may feel that science con-
sists of absolute facts, scientists know that all measure-
ment involves statistical variation and that the truth
involves showing a mean difference between two groups
of measurements that is statistically significant, replic-
able, and scientifically meaningful. Medicine, however, is
unique in that its focus and raison d’être involves the
individual [1]. A physician is interested in the mean
effect only to the extent that it gives him relevant infor-
mation about his individual patient. If his individual
patient is an outlier, his purpose as a physician is to find
the appropriate intervention for that individual and the
excuse that ‘your results are not in accord with the aver-
age’ never earned the gratitude of any patient. Thus,
individual differences are the basis of medical practice
rather than noise to be discarded in search of the true
effect hiding behind. One of the authors became acutely
aware of this after reexamining the data from his 1976
publication in Nature (see Figure 1) [2]. While the data
clearly show a powerful effect, and an effect that has
since been replicated, Figure 2 shows the individual dif-
ferences in this effect. These individual differences
might explain the current widely appreciated differences
in individual response of bipolar patients to lithium
treatment.
More recently, we have been working with knockout
mice that show low levels of brain inositol due to knock-
out of the inositol transporter [3]: we found that these
animals show a lithium-like phenotype (Figure 3). How-
ever, examination of the individual data showed the
results found in Figure 4. All three groups in this study
were genetically identical inbred animals handled in the
same way and living in the same laboratory conditions.
The individual differences cannot be ascribed to genetic
effects and could not easily be ascribed to environmental
effects as we commonly understand them. It is now
apparent that mRNA, even in cell lines grown in culture
of identical genetic origin, can vary greatly, suggesting
chaotic or as yet unexplained reasons for the large indivi-
dual differences [4]. The same is true of protein expres-
sion in isogenic bacterial populations [5]. These
individual differences are true in much of biological and
psychiatric experimentation, while they are perhaps more
recognized in clinical trials and clinical experimentation.
Often the publication style of data leads clinicians to
assume that effects are more uniform than the true nat-
ural variability. We recently published the results of a
small clinical trial of valnoctamide [6] as a new nontera-
togenic valproate substitute (see Figure 5). While we
clearly included the standard deviations and the results
were statistically significant, we found that most clini-
cians and indeed biological scientists who have seen our
paper interpret this effect as meaning that a patient trea-
ted with valnoctamide will uniformly do better than a
patient treated with placebo. This is not true, as Figure 6
will immediately illustrate [6]. More patients will do well* Correspondence: belmaker@bgu.ac.il
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Figure 1 The effect of lithium on plasma cAMP response to
adrenaline administration (from [2]with permission).



















Figure 2 Individual differences in the effect of lithium on plasma cAMP response to adrenaline administration (unpublished data from [2]).























Figure 3 The effect of sodium-dependent myo-inositol
cotransporter homozygote knockout or imipramine on
immobility after forced swim (from [3]with permission).
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with valnoctamide than placebo but many patients on
placebo will do well and many patients on valnoctamide
will do poorly. The importance of making this point
could be illustrated by looking at figure two in Vieta et
al. [7]. This paper showed that treatment of bipolar
depression with quetiapine, a second generation antipsy-
chotic, led to greater mean change from baseline in
depression scores than treatment with placebo. We have
found that this is almost universally interpreted by clini-
cians into an expectation that quetiapine is an effective
and powerful treatment of depression across the board
for patients who meet the diagnostic criterion for bipolar
depression. No standard deviations were shown to even
hint at the inter-patient variability. The result is that
many guidelines for the treatment of bipolar disorder list
effective treatments, those treatments shown to be better
than placebo, with little to guide the clinician as to make
choices between those effective treatments.
Conclusion
The truth of course is more likely that most psychiatric
disorders, like most medical disorders, are highly hetero-
geneous [8] and that the best tool we have for dissecting
that heterogeneity today is to take a careful history [9]. In
the absence of a history, careful follow-up is necessary
and often the best treatment for a particular patient will
appear only over time. The illusion that what is needed is
more head-to-head large trials without differentiating the
diagnosis of bipolar depression into subtypes could lead
to great expense but also to inappropriate treatment for
individual patients. Medicine must return to understand-
ing that individual differences are the essence of medi-
cine as opposed to those sciences that are interested
essentially in uncovering the grain of wheat from among
all the chaff. We in medicine are interested in each bit of
chaff or wheat, whoever and wherever he or she may be.
Perhaps Bayes’ Theorem might allow us to design more
appropriate medical experiments based on this concept
of individual differences. Recent papers on ‘patient-cen-
tered evidence’ [10] have emphasized this point as well as
the need to report heterogeneity in clinical trials [11].
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Figure 4 Individual differences in the effect of sodium-
dependent myo-inositol cotransporter homozygote knockout
or imipramine on immobility after forced swim (unpublished
data from [3]).
Figure 5 Efficacy of valnoctamide (n = 15) versus placebo (n =
17) as an add-on to risperidone in acute mania (unpublished
figure from [6]).
Figure 6 Individual differences in efficacy of valnoctamide (n =
15) versus placebo (n = 17) as an add-on to risperidone in
acute mania (unpublished data from [6]).
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